Teriparatide

Teriparatide (PTH 1-34) is a synthetic 34-amino-acid peptide consisting of the biologically active N-terminal fragment of human parathyroid hormone (PTH 1-84). It is administered as a once-daily subcutaneous injection of 20 mcg. It is sold as Forteo by Eli Lilly and as the follow-on product Bonsity (PF708) by Alvogen, both approved by the FDA. The mechanism is bone formation stimulation through intermittent PTH receptor activation on osteoblasts.

The molecule was developed in the 1990s based on the recognition that intermittent (rather than continuous) PTH signaling produces anabolic rather than catabolic effects on bone. Continuous high PTH (as in primary hyperparathyroidism) causes bone loss. Intermittent daily pulses of PTH (or its biologically active fragment) stimulate osteoblast activity and net bone formation. This distinction is the central pharmacological insight that made teriparatide a viable therapy.

FDA approval came on November 26, 2002 for postmenopausal osteoporosis in women at high risk for fracture and for primary or hypogonadal osteoporosis in men at high risk for fracture. The glucocorticoid-induced osteoporosis indication was added in 2009. The original Forteo patent expired in the US in 2019, and a follow-on product (PF708, now Bonsity) was approved through the 505(b)(2) pathway in October 2019.

The Pivotal Trial (Neer 2001)

The Fracture Prevention Trial (Neer et al., NEJM, 2001) is the foundational trial for teriparatide. Over 1,600 postmenopausal women with prior vertebral fractures were randomized to placebo, 20 mcg teriparatide, or 40 mcg teriparatide subcutaneously daily for a median of 21 months. Ninety percent of participants had at least one radiographically diagnosed vertebral fracture at baseline.

Vertebral fracture reduction was 65 percent at the 20 mcg dose and 69 percent at the 40 mcg dose versus placebo. Nonvertebral fracture reduction was 53 percent at the 20 mcg dose. Bone mineral density at the lumbar spine increased 9 percent at the 20 mcg dose and 13 percent at the 40 mcg dose over placebo. Femoral neck BMD increased 2 to 5 percent over placebo.

The trial was terminated early at 19 months when osteosarcoma was observed in Fischer 344 rats receiving teriparatide at high doses for near-lifetime exposure. The human trial was halted while the rat data were evaluated. This is the origin of the boxed warning that defined teriparatide labeling for nearly two decades.

The reduction in moderate-to-severe vertebral fractures (a clinically more important subgroup) was approximately 90 percent in both treatment groups. This is one of the largest fracture-reduction effects ever observed in osteoporosis pharmacotherapy.

VERO and GIO Trials

VERO trial (Kendler et al., Lancet 2018) compared teriparatide directly with risedronate (an oral bisphosphonate) in postmenopausal women with severe osteoporosis. Teriparatide reduced new vertebral fractures by 56 percent (5.4 percent vs 12.0 percent for risedronate, hazard ratio 0.44). Clinical fractures were reduced by 52 percent. VERO established teriparatide as superior to risedronate in patients with severe osteoporosis and high imminent fracture risk, supporting its use as first-line anabolic therapy in this population.

GIO (Glucocorticoid-Induced Osteoporosis) trial (Saag et al., NEJM 2007) randomized 428 men and women on chronic glucocorticoids to teriparatide 20 mcg daily or alendronate 10 mg daily for 18 months. Lumbar spine BMD increased 7.2 percent with teriparatide versus 3.4 percent with alendronate. Vertebral fracture rates were 0.6 percent with teriparatide versus 6.1 percent with alendronate. The trial supported the 2009 glucocorticoid-induced osteoporosis label addition.

DATA-HD study (Tsai et al., Lancet 2013) combined high-dose teriparatide (40 mcg) with denosumab (an antiresorptive antibody). The combination produced the largest BMD increases ever reported with any osteoporosis regimen, suggesting that higher teriparatide doses combined with antiresorptive therapy may produce additional benefit beyond the standard monotherapy approach.

Teriparatide acts on the PTH-1 receptor (PTH1R) expressed on osteoblasts and osteoblast precursors in bone. The receptor is also present on renal tubular cells, where it affects calcium and phosphate handling.

The anabolic effect on bone depends on the pulsatile pattern of receptor activation. A once-daily subcutaneous dose produces a brief peak in PTH receptor signaling, followed by return to baseline before the next dose. This pulsatile pattern preferentially activates osteoblast formation, mineralization, and bone matrix deposition. New bone is laid down faster than old bone is resorbed during the early treatment phase, producing the anabolic window of net bone gain.

The downstream cascade includes:

• Increased osteoblast number, activity, and lifespan (reduced apoptosis)
• Stimulation of bone matrix protein synthesis (type I collagen, osteocalcin)
• Increased trabecular and cortical bone formation
• Improved bone microarchitecture, particularly in trabecular sites like the lumbar spine

Continuous PTH receptor activation, by contrast, predominantly activates osteoclast-mediated bone resorption. This is the mechanism behind bone loss in primary hyperparathyroidism. Patients on teriparatide must adhere to once-daily dosing to maintain the pulsatile anabolic effect.

The anabolic window is finite. Bone formation accelerates fastest in the first 6 to 12 months, with diminishing additional gains between 12 and 24 months as the resorption-formation coupling narrows. Beyond 24 months, additional benefit is smaller. The original FDA labeling reflected this with a 2-year treatment limit.

Vertebral Fracture Reduction (Primary Endpoint Across Trials)

The most clinically important effect is vertebral fracture reduction.

Neer 2001 (Fracture Prevention Trial, postmenopausal osteoporosis): 65 percent reduction in new vertebral fractures at 20 mcg daily, 69 percent at 40 mcg, over 19 months. Moderate-to-severe vertebral fractures reduced approximately 90 percent.

Kendler 2018 (VERO, severe postmenopausal osteoporosis vs risedronate): 56 percent reduction in new vertebral fractures (5.4 percent on teriparatide vs 12.0 percent on risedronate, hazard ratio 0.44).

Saag 2007 (GIO, glucocorticoid-induced osteoporosis vs alendronate): Vertebral fracture rate 0.6 percent on teriparatide vs 6.1 percent on alendronate over 18 months.

Nonvertebral and Hip Fracture Reduction

Nonvertebral fractures: 53 percent reduction in Neer 2001 at the 20 mcg dose. The effect is statistically significant but smaller than the vertebral fracture effect, consistent with the larger trabecular component of vertebral bone and the larger BMD response at the lumbar spine compared with the femoral neck.

Hip fractures specifically: Not powered as a primary endpoint in any teriparatide trial. Meta-analyses suggest reduction in hip fracture rates but the absolute number of events in any single trial is too small to produce statistically significant individual-trial estimates.

Bone Mineral Density Increases

The BMD response is dose-dependent and site-dependent.

Lumbar spine BMD. Increases of 9 to 13 percent versus placebo at the 20 to 40 mcg doses over 18 to 21 months. Larger than any other osteoporosis intervention.

Femoral neck BMD. Increases of 2 to 5 percent versus placebo. Smaller than lumbar spine because cortical bone responds less than trabecular bone to anabolic therapy.

Total hip BMD. Increases of 2 to 4 percent versus placebo. The hip BMD response is the weak point of teriparatide compared with antiresorptive therapy and is one reason sequential therapy with denosumab or bisphosphonates is recommended.

1/3 radius BMD. May decrease slightly on teriparatide, an effect attributed to increased bone remodeling at predominantly cortical sites. This is generally not clinically significant.

Bone Microarchitecture

Teriparatide produces improved bone microarchitecture beyond simple BMD increase. High-resolution peripheral quantitative computed tomography (HR-pQCT) studies show:

• Increased trabecular thickness
• Increased trabecular number
• Improved trabecular connectivity
• Increased cortical thickness at some sites

The microarchitectural improvements partially explain why fracture reduction is larger than BMD increase alone would predict.

Time Course of Effect

The teriparatide response follows a predictable time course.

Months 1 to 6: Bone formation markers (P1NP, osteocalcin) rise rapidly. BMD begins to increase. Bone resorption markers also rise but to a smaller extent. The "anabolic window" is widest.

Months 6 to 12: Maximum rate of BMD increase. Most of the cumulative BMD gain occurs in this window.

Months 12 to 24: BMD continues to increase but at a slower rate. Bone resorption coupling narrows the anabolic window. Cumulative gain plateaus.

Beyond 24 months: Additional BMD gain is smaller. The original FDA labeling reflected this with a 2-year treatment limit, removed in November 2020.

Patient Subgroup Effects

Severe osteoporosis (multiple prior fractures or T-score worse than -3.5): Strongest response. Greatest absolute fracture risk reduction. The VERO trial supported teriparatide as preferred first-line therapy in this population.

Glucocorticoid-induced osteoporosis: Strong response in the GIO trial. The mechanism may relate to glucocorticoids' specific suppression of osteoblast activity, which teriparatide directly counteracts.

Male osteoporosis: Comparable response to female osteoporosis on BMD endpoints. The fracture-reduction database is smaller because trials in men have been smaller and shorter.

Hypogonadal osteoporosis: Approved indication. Less data than postmenopausal or glucocorticoid-induced disease.

Off-Label Use

Acceleration of fracture healing. Multiple small trials and case series have tested teriparatide for accelerating healing of acute fractures, particularly in non-osteoporotic populations such as pelvic insufficiency fractures, atypical femoral fractures (associated with bisphosphonate use), and complex orthopedic fractures. Results suggest accelerated callus formation and improved healing in some indications. None has FDA approval.

Osteonecrosis of the jaw (ONJ). Small case series suggest teriparatide may accelerate healing of bisphosphonate-related ONJ. Not approved.

Spinal fusion. Small studies suggest possible enhancement of spinal fusion outcomes in osteoporotic patients. Not approved.

None of the off-label uses has the trial-grade evidence backing of the approved osteoporosis indications.

Approved Forteo and Bonsity Label Dose

The FDA-approved dose for both Forteo (Lilly) and Bonsity (Alvogen, the 505(b)(2) follow-on) is 20 mcg subcutaneously once daily, administered into the thigh or abdominal wall.

The 20 mcg dose is the only dose in the approved label. Higher doses (40 mcg, used in research) produce marginally greater BMD response but with substantially more orthostatic hypotension and other adverse events. The 40 mcg dose is not commercially available and is not used in clinical practice.

Pen Device Administration

Forteo is supplied as a multi-dose pen device pre-filled with 600 mcg of teriparatide in 2.4 mL (250 mcg/mL concentration), sufficient for 28 daily doses. The pen is stored refrigerated and is single-patient-use only. Each daily injection delivers a fixed 20 mcg dose.

The pen is designed for subcutaneous administration in the abdominal wall or thigh. Patient injection technique training is provided at treatment initiation. After 28 days, any remaining medication in the pen is discarded.

Bonsity is also supplied as a pen device with the same dose and dosing pattern as Forteo.

Timing of Administration

The 20 mcg daily dose can be administered at any time of day. There is no specific time-of-day requirement in the label. Many patients administer in the evening because the most common adverse event (orthostatic hypotension within 4 hours of dosing) is easier to manage when followed by rest. Some patients administer in the morning for routine adherence.

Pharmacokinetics

Teriparatide has a plasma half-life of approximately 1 hour after subcutaneous injection. Peak plasma concentration occurs about 30 minutes after administration. The drug is cleared rapidly through hepatic and renal pathways. The short half-life is essential for the anabolic mechanism: it produces the pulsatile PTH receptor activation that drives bone formation rather than the continuous activation that drives bone resorption.

Peak serum calcium rise occurs approximately 4 to 6 hours after dosing and returns to baseline before the next daily dose. This pharmacokinetic pattern is preserved with consistent once-daily administration.

Treatment Duration

The original FDA label specified a 24-month lifetime treatment limit based on the concern about long-term osteosarcoma risk that emerged from the Fischer 344 rat data. The lifetime limit was removed in November 2020 after 15+ years of post-approval safety data did not identify increased osteosarcoma risk in human patients.

Current clinical practice typically treats with teriparatide for 18 to 24 months, followed by transition to antiresorptive therapy. The transition is essential because BMD gains achieved during anabolic treatment are rapidly lost if treatment is stopped without subsequent antiresorptive therapy. Sequential teriparatide-then-bisphosphonate or teriparatide-then-denosumab is the standard approach.

Some patients receive longer than 24 months of teriparatide based on individualized clinical judgment, particularly in severe osteoporosis where ongoing anabolic effect is the priority. Re-treatment with a second course of teriparatide is also possible in selected patients.

Combination Protocols

DATA-HD study (Tsai 2013) approach. Combined high-dose teriparatide (40 mcg) with denosumab. Produced the largest BMD gains reported with any osteoporosis regimen. Not FDA-approved as a combination, but the data informs sequential treatment decisions.

Standard sequential approach. Teriparatide for 18 to 24 months, followed by denosumab or oral/IV bisphosphonate for indefinite duration to preserve the BMD gains. This pattern has supportive data from observational and randomized switch studies.

Reverse-sequence (antiresorptive then teriparatide). Has been studied but produces smaller BMD increases than the anabolic-first approach. Bisphosphonate pre-treatment appears to blunt the teriparatide response on some sites, particularly the hip.

Why 20 mcg Is the Approved Dose

The 40 mcg dose tested in Neer 2001 produced only modestly larger fracture reduction (69 percent vs 65 percent for vertebral fractures) and BMD increase (13 percent vs 9 percent at lumbar spine) compared with the 20 mcg dose. The 40 mcg dose was associated with substantially higher rates of orthostatic hypotension, nausea, headache, and hypercalcemia. The therapeutic index favored 20 mcg as the approved dose. The pen device is calibrated to deliver 20 mcg, with no labeled provision for dose adjustment.

The cumulative safety database covers more than 1 million patient-years of treatment in the post-marketing era. The most common adverse events at the labeled 20 mcg daily dose are:

Orthostatic hypotension in approximately 5 to 10 percent of patients, typically within 4 hours of dosing. Generally mild and tolerable. Patients are advised to administer the injection seated or in a position where they can sit or lie down if dizziness occurs.

Nausea in approximately 10 percent of patients. Generally mild.

Headache in 8 percent.

Leg cramps at slightly increased rates compared with placebo.

Transient serum calcium increase approximately 4 to 6 hours after dosing, returning to baseline before the next dose. Clinically significant hypercalcemia is rare.

Antibody formation against teriparatide was detected in 3 percent of patients in the Phase 3 trials, generally after 12 months of treatment. Antibodies diminished after withdrawal. No hypersensitivity reactions or allergic reactions resulted, and antibody formation did not appear to affect treatment efficacy.

Osteosarcoma signal has not emerged in cumulative post-marketing data despite the original boxed warning. Five real-world studies and post-approval registries have not identified increased osteosarcoma risk in human patients. The 2020 boxed warning removal reflected this evidence.

Theoretical malignancy considerations. Patients with Paget's disease, history of skeletal radiation, bone metastases, or other conditions associated with increased baseline osteosarcoma risk are generally not candidates for teriparatide. Severe renal impairment (creatinine clearance below 30 mL/min) requires dose adjustment.

Abaloparatide (Tymlos) is a PTHrP (parathyroid hormone-related protein) analog approved for postmenopausal osteoporosis in 2017. It targets the same PTH1R receptor with different signaling bias. Direct comparison trials suggest comparable efficacy with possibly better hip BMD effects and a slightly different adverse-event profile.

Romosozumab (Evenity) is a monoclonal antibody to sclerostin (a bone-formation inhibitor). It is dosed monthly and produces both anabolic (bone formation) and antiresorptive (reduced bone resorption) effects. Cardiovascular safety signals have led to specific patient-selection criteria.

Bisphosphonates and denosumab are antiresorptive (rather than anabolic) and represent the alternative class. They reduce bone breakdown without stimulating new bone formation. Teriparatide is typically reserved for patients with severe osteoporosis, multiple vertebral fractures, or failure of antiresorptive therapy.

For sequential anabolic-then-antiresorptive regimens, the standard approach is teriparatide for 12 to 24 months followed by a bisphosphonate or denosumab to preserve the BMD gains. Stopping teriparatide without later antiresorptive therapy results in rapid loss of the BMD gained during anabolic treatment.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.